The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
On June 28, Chuansha Park of Shanghai Medicilon Inc. (Medicilon) welcomed familiar customers – Dr. Yan Feng, Founder and CEO of Leading Tac Pharma, Dr. Juan XU, VP of Bioanalysis and Proteomics, and a group of colleagues. This time, Dr. Feng Yan and his party visited Medicilon in person, just to award the Medicilon DMPK team the “Best Partner Award” to express their gratitude and recognition. Professor Shuangqing Peng, Chief Scientific Officer of Medicilon, and Dr. Pin Jiang, Director of the Department of Pharmacokinetics and Bioanalysis, warmly received and had an fruitful discussion.
During the symposium, the two parties actively interacted, offered suggestions, shared the latest scientific and technological achievements and R&D experience around their respective advantages and needs, discussed in depth the status quo, development trends of the biomedical industry, and project R&D strategies, and clarified the next step of the project’s planning and deployment, laying a solid foundation for further collaboration between the two parties.
At the awarding ceremony, Dr. Feng affirmed Medicilon’s consistently rigorous, efficient and high-quality preclinical R&D services, and praised Medicilon’s dedicated work attitude in DMPK, bioanalysis, and project management. He then expressed his sincere gratitude and awarded honorary trophies to Medicilon DMPK team. The DMPK team has a group of senior professionals with solid knowledge and rich experimental experience, leading the work of experimental design, experimental implementation, biological analysis and data analysis. At present, the pharmacokinetic laboratory has passed the GLP certification of NMPA. The experimental research follows the guidelines of ICH, NMPA and FDA, and can design and carry out in vivo and in vitro pharmacokinetic tests according to client needs, providing clients with a complete set of pharmacokinetic evaluation and optimization services.
About Leading Tac Pharma
Founded in 2019, Leading Tac Pharma is a biopharmaceutical company dedicated to the research and development of First-in-class/Best-in-class small molecule innovative drugs. With Targeted Protein Degradation (TPD) drug development technology as the core, it focuses on autoimmunity and tumors, two therapeutic areas with important market opportunities and synergistic effects, to provide patients with breakthrough treatment options. Leading Tac Pharma is located in Zhangjiang Science City, Shanghai, China. The existing laboratory and office area is nearly 1,000 square meters, and there are 20 employees. It has completed financing of nearly RMB 100 million since its establishment 3 years ago.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
